by Alan McCann | Jan 20, 2022 | Uncategorized
Fibralign is hosting the inaugural Lymphedema Summit on January 23- Fibralign is hosting the inaugural Lymphedema Summit on January 23, an international research seminar focused on “Advancements in Lymphedema Surgical Treatment.” For more details:...
by fibralign | Jun 10, 2021 | Uncategorized
NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment SAN FRANCISCO, June 10, 2021 /PRNewswire/ — The UCSF Rosenman Institute is proud to announce the 2021 cohort of the Rosenman Innovators, a group of early-stage health...
by fibralign | Apr 15, 2021 | Uncategorized
NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment April 14, 2021 – The University of Chicago Medicine has announced today that it is now enrolling patients into LymphBridge™, a randomized clinical study to evaluate a...
by Alan McCann | Feb 9, 2021 | Uncategorized
Multi-site clinical study to evaluate BioBridge® as prophylactic treatment for at-risk patients UNION CITY, Calif.–(BUSINESS WIRE)–Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of...
by Alan McCann | Sep 14, 2020 | Uncategorized
European approval for novel device supporting surgical treatment of lymphedema September 14, 2020 (Union City, CA) – Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first...
by Alan McCann | Jun 3, 2020 | Uncategorized
Exclusive agreement for Terumo to market and distribute Fibralign’s BioBridge in Japan June 02, 2020 06:00 AM Eastern Daylight Time UNION CITY, Calif.–(BUSINESS WIRE)–Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has...
